Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company’s strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences to Acquire Kineta, Inc. in 2025
- TuHURA Biosciences enters definitive merger agreement to acquire Kineta
- HURA, SVR, HUC: 3 Commodity ETFs to Hedge against Inflation
- TuHURA Biosciences Advances in Cancer Immunotherapy Innovations
- TuHURA Biosciences announces upcoming milestone targets